Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
08/23/20166:59AMBWBristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016
Nineteen abstracts to be presented, including new post-hoc sub-analyses from the ARISTOTLE Phase 3 trial and multiple retrospective real-world data analyses from ACROPOLIS Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations... More...>>
08/11/20163:04AMDJNBusiness Watch -- WSJ
SAMSUNG GROUP Drug Unit Plans $2.5 Billion IPO Samsung BioLogics Co., the contract drug-manufacturing unit of South Korean conglomerate Samsung Group, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion, according to people familiar with the matter. The... More...>>
08/10/20164:10AMDJNSamsung BioLogics Aims to Raise Up to $2.5 Billion From IPO
Samsung BioLogics Co., the contract drug manufacturing unit of South Korean conglomerate Samsung Group, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion, according to people familiar with the matter. The company, which manufactures complex biologic... More...>>
08/05/201611:43PMDJNWhat's News: Business & Finance
The U.S. labor market in July capped the best two-month stretch of hiring so far this year despite global turbulence and slower business spending, posing a challenge for the Fed. The Nasdaq rose to a record, signaling renewed appetite for risk. The S&P 500 also closed at a high. The Dow gained 191.48 points. A cancer... More...>>
08/05/201612:58PMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--4th Update
By Peter Loftus, Jonathan D. Rockoff and Anne Steele In a surprise finding that raises questions about the potential for a new class of cancer drugs that harness the body's immune system, Bristol-Myers Squibb Co. said its drug Opdivo wasn't significantly better than chemotherapy in a study of patients with newly... More...>>
08/05/201610:36AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--3rd Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.21 in early trading, erasing roughly $22 billion of the company's market value and... More...>>
08/05/201610:15AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--2nd Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 16% to $63.07 in early trading. Meanwhile, shares of Merck & Co. rose 5.6% as the result suggests... More...>>
08/05/20169:39AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 19% to $61 in premarket trading. Meanwhile, shares of Merck & Co. rose 11% as the results suggest... More...>>
08/05/20169:20AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study
Bristol-Myers Squibb Co. said results for a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.60 in premarket trading. Meanwhile, shares of Merck & Co. rose 10% as the results suggest... More...>>
08/05/20169:12AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study
By Anne Steele Bristol-Myers Squibb Co. said results for a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.60 in premarket trading. Meanwhile, shares of Merck & Co. rose 10% as the... More...>>
08/05/20168:20AMBWBristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïv...
Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 ≥ 5% Bristol-Myers Squibb Company (NYSE:BMY) announced today that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in... More...>>
08/03/20164:15PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-eight cents ($0.38) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 1, 2016, to stockholders of record at the close of business on October... More...>>
07/29/20161:47PMDJNMerck Revenue Rises on Cancer, Hepatitis Treatments -- Update
By Peter Loftus and Austen Hufford Merck & Co. posted an unexpected increase in second-quarter revenue thanks to new cancer and hepatitis treatments, and an increased profit versus a year-earlier period that was weighed down by foreign-exchange losses. The drugmaker also tightened its full-year 2016 financial forecast... More...>>
07/28/20161:26PMDJNBristol-Myers Results Boosted by Cancer Drugs -- Update
By Jonathan D. Rockoff and Tess Stynes Bristol-Myers Squibb Co. said its second-quarter revenue rose 17% and it raised its earnings forecast for the year as the company's bet on cancer immunotherapies continues to pay off while other drugs show gains. The drugmaker was the first to bring to market an immunotherapy... More...>>
07/28/20167:50AMDJNBristol-Myers Results Boosted by Cancer Drugs
Bristol-Myers Squibb Co. said its second-quarter revenue rose 17%, again driven by the growth of the pharmaceutical company's Opdivo cancer immunotherapy and other key drugs. Per-share earnings and revenue beat expectations, and the company also raised its 2016 guidance. For the year, Bristol-Myers now expects per-share... More...>>
07/28/20167:30AMDJNBristol-Myers Results Boosted by Cancer Drugs
By Tess Stynes Bristol-Myers Squibb Co. said its second-quarter revenue rose 17%, again driven by the growth of the pharmaceutical company's Opdivo cancer immunotherapy and other key drugs. Per-share earnings and revenue beat expectations, and the company also raised its 2016 guidance. For the year, Bristol-Myers... More...>>
07/28/20166:59AMBWBristol-Myers Squibb Reports Second Quarter Financial Results
Increases Second Quarter Revenues 17% to $4.9 Billion Posts Second Quarter GAAP and Non-GAAP EPS of $0.69 Achieves Important Regulatory Milestones in Immuno-Oncology Opdivo + Yervoy Regimen Approved in Europe for Metastatic Melanoma Opdivo Approved in the U.S. for the Treatment of Classical Hodgkin Lymphoma Opdivo Granted... More...>>
07/27/20166:10PMDJNExperimental Alzheimer's Drug Fails in Trial
An experimental drug for Alzheimer's targeting a protein called tau failed to improve patients' cognition or daily functioning in a clinical trial, dealing a setback to a closely watched segment of research. The treatment, from Singapore-based drugmaker TauRx Pharmaceuticals Ltd., was the first tau-targeted therapy... More...>>
07/26/20166:59AMBWBristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer
Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin... More...>>
07/25/201611:00AMBWBristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.D., has been appointed Oncology Development Head, effective July 25, 2016. Dr. Namouni will be responsible for leading the execution of a comprehensive development strategy for the company’s robust oncology pipeline from the early development... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20160831 06:16:38